Total Payments
$8,935
2024 Payments
$141.66
Companies
53
Transactions
463
Medicare Patients
2,279
Medicare Billing
$816,652
Payment Breakdown by Category
Food & Beverage$7,087 (79.3%)
Consulting$550.00 (6.2%)
Other$530.00 (5.9%)
Education$449.35 (5.0%)
Travel$318.86 (3.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,087 | 439 | 79.3% |
| Consulting Fee | $550.00 | 4 | 6.2% |
| Education | $449.35 | 15 | 5.0% |
| Honoraria | $425.00 | 2 | 4.8% |
| Travel and Lodging | $318.86 | 2 | 3.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $105.00 | 1 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $937.59 | 73 | $0 (2020) |
| PFIZER INC. | $710.72 | 57 | $0 (2022) |
| Genentech USA, Inc. | $655.43 | 51 | $0 (2020) |
| COMSORT, Inc | $550.00 | 4 | $0 (2019) |
| Heron Therapeutics, Inc. | $513.74 | 3 | $0 (2017) |
| Amgen Inc. | $459.12 | 19 | $0 (2022) |
| Celgene Corporation | $437.79 | 30 | $0 (2019) |
| Janssen Biotech, Inc. | $412.26 | 20 | $0 (2024) |
| Merck Sharp & Dohme LLC | $405.66 | 31 | $0 (2024) |
| GENZYME CORPORATION | $298.71 | 11 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $141.66 | 6 | Janssen Biotech, Inc. ($40.78) |
| 2023 | $180.90 | 7 | Mirati Therapeutics, Inc. ($113.69) |
| 2022 | $577.73 | 19 | Novocure GmbH ($250.00) |
| 2021 | $244.92 | 5 | Amgen Inc. ($199.90) |
| 2020 | $609.25 | 21 | Athenex Pharmaceutical Division, LLC ($175.00) |
| 2019 | $1,825 | 104 | PFIZER INC. ($211.48) |
| 2018 | $2,555 | 151 | E.R. Squibb & Sons, L.L.C. ($568.03) |
| 2017 | $2,801 | 150 | Heron Therapeutics, Inc. ($513.74) |
All Payment Transactions
463 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/19/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $40.78 | General |
| Category: Oncology | ||||||
| 06/07/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $25.01 | General |
| Category: ONCOLOGY | ||||||
| 06/04/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $17.48 | General |
| 05/23/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $15.73 | General |
| Category: Oncology | ||||||
| 05/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $21.39 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $34.32 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2023 | Foundation Medicine, Inc. | FOUNDATIONONE LIQUID CDX | Food and Beverage | In-kind items and services | $16.86 | General |
| 10/12/2023 | Pharmacyclics LLC, An AbbVie Company | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $25.89 | General |
| Category: ONCOLOGY | ||||||
| 08/16/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $22.20 | General |
| Category: ONCOLOGY | ||||||
| 06/08/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $39.60 | General |
| Category: ONCOLOGY | ||||||
| 05/04/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $24.46 | General |
| Category: ONCOLOGY | ||||||
| 02/03/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $17.57 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $22.66 | General |
| Category: ONCOLOGY | ||||||
| 10/05/2022 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: ONCOLOGY | ||||||
| 09/21/2022 | Amgen Inc. | Blincyto (Biological) | Food and Beverage | In-kind items and services | $18.76 | General |
| Category: Oncology | ||||||
| 09/07/2022 | Amgen Inc. | LUMAKRAS (Drug) | Food and Beverage | In-kind items and services | $12.43 | General |
| Category: Oncology | ||||||
| 08/24/2022 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $14.80 | General |
| Category: Oncology | ||||||
| 08/10/2022 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $22.33 | General |
| Category: HEMATOLOGY | ||||||
| 06/22/2022 | Amgen Inc. | Nplate (Biological), XGEVA | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: Hematology | ||||||
| 06/01/2022 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $15.27 | General |
| 05/31/2022 | Amgen Inc. | LUMAKRAS (Drug) | Food and Beverage | In-kind items and services | $13.36 | General |
| Category: Oncology | ||||||
| 05/18/2022 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $21.19 | General |
| Category: Oncology | ||||||
| 05/11/2022 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Food and Beverage | In-kind items and services | $23.59 | General |
| Category: ONCOLOGY | ||||||
| 05/03/2022 | Amgen Inc. | Nplate (Biological), XGEVA | Food and Beverage | In-kind items and services | $14.26 | General |
| Category: Hematology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 424 | 759 | $147,426 | $43,341 |
| 2022 | 7 | 492 | 808 | $168,249 | $55,737 |
| 2020 | 32 | 1,363 | 20,572 | $1.7M | $717,574 |
Total Patients
2,279
Total Services
22,139
Medicare Billing
$816,652
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 228 | 522 | $93,960 | $27,839 | 29.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 60 | 99 | $24,750 | $7,584 | 30.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 63 | 63 | $15,246 | $4,607 | 30.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $5,400 | $1,469 | 27.2% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 26 | 26 | $4,160 | $1,008 | 24.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 32 | 34 | $3,910 | $833.66 | 21.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 201 | 379 | $68,220 | $21,782 | 31.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 91 | 225 | $56,250 | $20,254 | 36.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 72 | 72 | $17,424 | $5,225 | 30.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 30 | 30 | $10,800 | $3,537 | 32.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 57 | 61 | $7,015 | $2,034 | 29.0% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 30 | 30 | $4,800 | $1,453 | 30.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 11 | 11 | $3,740 | $1,453 | 38.9% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2020 | 13 | 7,800 | $655,200 | $307,375 | 46.9% |
| J2505 | Injection, pegfilgrastim, 6 mg | Office | 2020 | 26 | 59 | $466,985 | $193,572 | 41.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 39 | 7,020 | $224,640 | $105,287 | 46.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 230 | 472 | $68,912 | $32,643 | 47.4% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 68 | 242 | $90,508 | $23,172 | 25.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 63 | 63 | $17,073 | $9,283 | 54.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 141 | 150 | $14,850 | $6,384 | 43.0% |
| 96417 | Infusion of different chemotherapy drug or substance into a vein up to 1 hour | Office | 2020 | 28 | 101 | $18,382 | $4,961 | 27.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 28 | 30 | $7,470 | $4,667 | 62.5% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2020 | 24 | 940 | $47,000 | $4,577 | 9.7% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2020 | 52 | 335 | $19,095 | $4,029 | 21.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 35 | 39 | $7,644 | $3,461 | 45.3% |
About Dr. Niraj Gupta, MD
Dr. Niraj Gupta, MD is a Hematology & Oncology healthcare provider based in Carmel, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790717510.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Niraj Gupta, MD has received a total of $8,935 in payments from pharmaceutical and medical device companies, with $141.66 received in 2024. These payments were reported across 463 transactions from 53 companies. The most common payment nature is "Food and Beverage" ($7,087).
As a Medicare-enrolled provider, Gupta has provided services to 2,279 Medicare beneficiaries, totaling 22,139 services with total Medicare billing of $816,652. Data is available for 3 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Internal Medicine
- Location Carmel, IN
- Active Since 07/06/2006
- Last Updated 03/08/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1790717510
Products in Payments
- KEYTRUDA (Biological) $880.13
- OPDIVO (Biological) $671.58
- SUSTOL (Drug) $513.74
- IMBRUVICA (Drug) $360.11
- Abraxane (Drug) $307.38
- IBRANCE (Drug) $241.79
- Avastin (Biological) $240.46
- Imbruvica (Drug) $227.76
- SUTENT (Drug) $188.72
- ELITEK (Drug) $171.33
- TAGRISSO (Drug) $167.24
- ELIQUIS (Drug) $161.97
- BioZorb (Device) $156.20
- Cabometyx (Drug) $125.66
- ZEJULA (Drug) $120.22
- Nerlynx (Drug) $118.89
- KRAZATI (Drug) $113.69
- Pomalyst (Drug) $111.25
- GILOTRIF (Drug) $106.42
- TECENTRIQ (Biological) $103.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.